NEW YORK (GenomeWeb News) – Epigenomics today reported that its first-half 2009 revenues increased 37 percent, due to income from licensing agreements, and its net loss fell 14 percent year over year.

The German molecular diagnostics developer said that it had first-half revenues of €2.1 million ($3 million), compared to first-half 2008 revenues of €1.5 million. The firm said that its revenue came from R&D payments, licensing fees, reimbursements, and product sales from its research-use-only kits.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.